Recently, the world witnessed the approval of the world’s first two iPSC-derived medicines, as Japan’s health ministry panel authorized their commercialization on February 19, 2026. The approved therapies are ReHeart, developed by Cuorips Inc., a regenerative medicine company spun out of research at Osaka University, and Amchepry, developed by Sumitomo Pharma Co., Ltd. in collaboration with Racthera Inc. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
AABB Releases New Exam Prep Bundles For its Certified Advanced Biotherapies Professional (CABP) Credentialing Program
April 1, 2026, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the launch of two new exam prep bundles for its Certified Advanced Biotherapies Professional (CABP) credentialing program: the CABP Exam Prep Complete Bundle and the CABP Exam Prep Core Bundle. The new bundles are designed to help candidates prepare for AABB’s CABP exam. [Read more…]
Gameto Licenses Foundational Meiosis IP from Harvard to Advance Human Ovary-in-a-Dish Platform
Newly licensed intellectual property enables genetic induction of early meiosis, further strengthening Gameto’s best-in-class platform for modeling human ovarian development and disease
AUSTIN, Texas, Jan. 29, 2026 –– Gameto, a clinical-stage biotechnology company advancing cell engineering solutions for women’s health, announced that it has exclusively licensed additional intellectual property from Harvard University related to the induction of meiosis in human cells. The IP builds upon prior work conducted under Gameto’s sponsored research agreement with George Church’s laboratory at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering.
Green Elephant Biotech Introduces Archimedes® One, the First Dynamic Adherent Bioreactor for Cell Therapy Manufacturing
Giessen, Germany – 17.03.2026 – Green Elephant Biotech announces the market introduction of Archimedes® One, the first system in a new category called the Dynamic Adherent Bioreactor. The company is introducing the platform to the market ahead of its planned commercial launch later this year.
Archimedes® One was developed to address a central challenge in cell therapy manufacturing: how to scale adherent cell processes without compromising biology or introducing unnecessary complexity. [Read more…]
Longevity Medical Institute® Publishes Systematic Review of Stem Cell Safety Based on Landmark Human Clinical Trials
LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 17, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the safety of allogeneic mesenchymal stem cell therapies across a broad range of human clinical indications.
The study, titled “Safety of Allogeneic Mesenchymal Stromal Cell Therapy Across Human Clinical Indications: A Systematic Review of Landmark Clinical Trials and Published Safety Evidence,” reviewed more than 15 years of published human clinical research across more than 60 stem cell studies, approximately 4,000 patients, and multiple disease categories, including cardiovascular, pulmonary, autoimmune, gastrointestinal, renal, and orthopedic conditions. [Read more…]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 144
- Next Page »